Contact
searchSearch
HMP Global
Login

NRG1 News

News
Zenocutuzumab Demonstrates Durable Efficacy for Patients With NRG1-Positive Cholangiocarcinoma
12/02/2025
Stephanie Holland
According to updated results from the ongoing, phase 2 eNRGy trial, zenocutuzumab demonstrated durable efficacy and safety among patients with NRG1-positive cholangiocarcinoma.
According to updated results from the ongoing, phase 2 eNRGy trial, zenocutuzumab demonstrated durable efficacy and safety among patients with NRG1-positive cholangiocarcinoma.
According to updated results...
12/02/2025
Oncology
News
FDA Grants Breakthrough Therapy Designation to Zenocutuzumab for Patients With Advanced NRG1-Positive Cholangiocarcinoma
10/30/2025
Stephanie Holland
Based on updated results from the phase 2 eNRGy trial, the FDA has granted Breakthrough Therapy designation to zenocutuzumab for the treatment of patients with advanced unresectable or metastatic NRG1-positive cholangiocarcinoma.
Based on updated results from the phase 2 eNRGy trial, the FDA has granted Breakthrough Therapy designation to zenocutuzumab for the treatment of patients with advanced unresectable or metastatic NRG1-positive cholangiocarcinoma.
Based on updated results from...
10/30/2025
Oncology
News
The Distinct Gene Landscape of Neuregulin 1 Fusions
09/30/2025
Allison Casey
According to a retrospective study, patients with NRG1 fusions have distinct genetic and molecular characteristics.
According to a retrospective study, patients with NRG1 fusions have distinct genetic and molecular characteristics.
According to a retrospective...
09/30/2025
Oncology
News
Neuregulin 1 Variants of Uncertain Significance Associated With Poor Prognosis in Advanced Non-Small Cell Lung Cancer
09/18/2025
Allison Casey
According to a retrospective analysis, neuregulin 1 variants of uncertain significance were associated with poor prognosis, and other oncogene alterations, in advanced non-small cell lung cancer.
According to a retrospective analysis, neuregulin 1 variants of uncertain significance were associated with poor prognosis, and other oncogene alterations, in advanced non-small cell lung cancer.
According to a retrospective...
09/18/2025
Oncology
News
NRG1 May Predict Incidence of CRPC Among Patients With Prostate Cancer
08/05/2025
Allison Casey
NRG1 levels prior to ADT may assist in predicting castration-resistant prostate cancer among patients with prostate cancer receiving ADT.
NRG1 levels prior to ADT may assist in predicting castration-resistant prostate cancer among patients with prostate cancer receiving ADT.
NRG1 levels prior to ADT may...
08/05/2025
Oncology
News
Potential Therapeutic Targets for Patients With Invasive Mucinous Adenocarcinoma
07/24/2025
Allison Casey
A recent study found invasive mucinous adenocarcinomas have a higher likelihood of harboring KRAS mutations and NRG fusion genes.
A recent study found invasive mucinous adenocarcinomas have a higher likelihood of harboring KRAS mutations and NRG fusion genes.
A recent study found invasive...
07/24/2025
Oncology
News
Potential Activity of Afatinib Among Patients With Advanced Solid Tumors With NGR1 Fusions
05/06/2025
Allison Casey
According to a case series of patients enrolled in the TAPUR trial, afatinib showed promising activity among patients with advanced solid tumors harboring neuregulin 1 fusions.
According to a case series of patients enrolled in the TAPUR trial, afatinib showed promising activity among patients with advanced solid tumors harboring neuregulin 1 fusions.
According to a case series of...
05/06/2025
Oncology
News
The Potential of Targeting NRG1 for Esophageal Squamous Cell Carcinoma
04/10/2025
Allison Casey
Targeting NRG1 may present a potential treatment strategy for esophageal squamous cell carcinoma.
Targeting NRG1 may present a potential treatment strategy for esophageal squamous cell carcinoma.
Targeting NRG1 may present a...
04/10/2025
Oncology
News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors
03/31/2025
Janelle Bradley
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study...
03/31/2025
Oncology
News
FDA Approves Zenocutuzumab for Patients With NRG1 Fusion-Positive Non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma
12/04/2024
Stephanie Holland
Based on results from the eNRGy study, the FDA has approved zenocutuzumab for adult patients with advanced, unresectable, or metastatic NRG1 fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma who have progressed on or...
Based on results from the eNRGy study, the FDA has approved zenocutuzumab for adult patients with advanced, unresectable, or metastatic NRG1 fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma who have progressed on or...
Based on results from the eNRGy...
12/04/2024
Oncology

Recent News

News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use